Heart failure & cardiomyopathiesSecondary analysis
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin
- Secondary analysis of the CHIEF-HF randomised trial
- placebo-controlled
Authors' conclusion
After canagliflozin therapy, regardless of EF, modeling shows the KCCQ-TSS improves rapidly with the greatest improvements occurring within the first weeks of treatment.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) treated with canagliflozin 100 mg or placebo for 12 weeks
- Participants
- 448 patients
- Comparison
- HFpEF vs HFrEF
- HFpEFn = 267
- HFrEFn = 181reference
- Primary endpoint
- Rate of change (slope) in KCCQ-TSS, assessed at baseline and 2, 4, 6 and 12 weeks
- Follow-up
- 12 weeks
Primary result
Rate of KCCQ-TSS change with canagliflozin
Difference
0.2 points/day
95% CI −0.4 to 0.7
P = 056
By group
HFpEF vs HFrEF
difference 0.2 points/day (95% CI −0.4 to 0.7); P = 056
As reported in the abstract
Further findings
| Outcome | HFpEF | HFrEF |
|---|---|---|
| Baseline KCCQ-TSS | 54 ± 21 | 64 ± 20 |
Original publication
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin. JACC Heart Fail. Published 21 February 2024. doi:10.1016/j.jchf.2024.01.005
Summarised from the published abstract; every number is checked against it